A detailed history of Avidity Partners Management LP transactions in Argenx Se stock. As of the latest transaction made, Avidity Partners Management LP holds 38,200 shares of ARGX stock, worth $23.8 Million. This represents 1.27% of its overall portfolio holdings.

Number of Shares
38,200
Previous 60,500 36.86%
Holding current value
$23.8 Million
Previous $26 Million 20.37%
% of portfolio
1.27%
Previous 1.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $9.68 Million - $12.3 Million
-22,300 Reduced 36.86%
38,200 $20.7 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $21.5 Million - $27.3 Million
60,500 New
60,500 $26 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $16.8 Million - $25.1 Million
-49,600 Reduced 61.54%
31,000 $11.8 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $38.3 Million - $56.9 Million
-103,700 Reduced 56.27%
80,600 $39.6 Million
Q2 2023

Aug 14, 2023

SELL
$360.14 - $422.58 $34.7 Million - $40.7 Million
-96,400 Reduced 34.34%
184,300 $71.8 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $115 Million - $139 Million
-344,300 Reduced 55.09%
280,700 $105 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $45.6 Million - $53.6 Million
133,200 Added 27.08%
625,000 $237 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $27.7 Million - $31.9 Million
-80,700 Reduced 14.1%
491,800 $174 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $107 Million - $150 Million
396,500 Added 225.28%
572,500 $217 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $44.8 Million - $61.8 Million
176,000 New
176,000 $55.5 Million
Q2 2021

Aug 16, 2021

SELL
$257.11 - $319.92 $5.14 Million - $6.4 Million
-20,000 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $5.37 Million - $7.61 Million
20,000 New
20,000 $5.51 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.